多发性骨髓瘤患者对BNT162b2免疫接种的T细胞反应严重受损。 - Suppr

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

作者信息

Enßle Julius C, Campe Julia, Schwenger Amelie, Wiercinska Eliza, Hellstern Helen, Dürrwald Ralf, Rieger Michael A, Wolf Sebastian, Ballo Olivier, Steffen Björn, Serve Hubert, Bonig Halvard, Rabenau Holger F, Widera Marek, Ciesek Sandra, Metzler Ivana von, Ullrich Evelyn

机构信息

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.

出版信息

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

DOI:10.1182/blood.2021013429

PMID:34657156

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8734828/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/488cbee42a5f/gr1_lrg.jpg

相似文献

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.

Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.

Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.

Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16.

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.

Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.

Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.

Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.

Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.

Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.

Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.

Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.

Nat Commun. 2022 Feb 14;13(1):864. doi: 10.1038/s41467-022-28578-0.

引用本文的文献

Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.

Ann Hematol. 2025 May;104(5):2813-2821. doi: 10.1007/s00277-025-06367-1. Epub 2025 May 15.

Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.

Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.

Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.

Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.

Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.

BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.

Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.

Leukemia. 2024 Jan;38(1):168-180. doi: 10.1038/s41375-023-02070-0. Epub 2023 Dec 4.

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.

Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.

Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023.

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.

Front Oncol. 2023 Apr 21;13:1078725. doi: 10.3389/fonc.2023.1078725. eCollection 2023.

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.

Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia.

Cancer Med. 2023 Jun;12(12):13135-13144. doi: 10.1002/cam4.5996. Epub 2023 Apr 26.

本文引用的文献

Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Blood Cancer Discov. 2020 Nov 4;1(3):290. doi: 10.1158/2643-3230.BCD-20-0160. eCollection 2020 Nov.

COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.

J Mol Med (Berl). 2022 Mar;100(3):463-470. doi: 10.1007/s00109-021-02114-x. Epub 2021 Oct 18.

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.

Eur J Cancer. 2021 Sep;154:66-72. doi: 10.1016/j.ejca.2021.06.008. Epub 2021 Jun 18.

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.

Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.

Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.

Seroconversion rates following COVID-19 vaccination among patients with cancer.

Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.

J Clin Med. 2021 May 14;10(10):2128. doi: 10.3390/jcm10102128.

CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Nat Med. 2021 Jul;27(7):1280-1289. doi: 10.1038/s41591-021-01386-7. Epub 2021 May 20.

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.

Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

作者信息

机构信息

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.

出版信息

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

DOI:10.1182/blood.2021013429

PMID:34657156

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8734828/

Abstract

摘要

相似文献

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.

Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.

Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.

Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16.

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.

Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.

Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.

Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.

Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.

Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.

Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.

Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.

Nat Commun. 2022 Feb 14;13(1):864. doi: 10.1038/s41467-022-28578-0.

引用本文的文献

Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.

Ann Hematol. 2025 May;104(5):2813-2821. doi: 10.1007/s00277-025-06367-1. Epub 2025 May 15.

Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.

Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.

Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.

Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.

Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.

BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.

Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.

Leukemia. 2024 Jan;38(1):168-180. doi: 10.1038/s41375-023-02070-0. Epub 2023 Dec 4.

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.

Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.

Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023.

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.

Front Oncol. 2023 Apr 21;13:1078725. doi: 10.3389/fonc.2023.1078725. eCollection 2023.

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.

Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia.

Cancer Med. 2023 Jun;12(12):13135-13144. doi: 10.1002/cam4.5996. Epub 2023 Apr 26.

本文引用的文献

Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Blood Cancer Discov. 2020 Nov 4;1(3):290. doi: 10.1158/2643-3230.BCD-20-0160. eCollection 2020 Nov.

COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.

J Mol Med (Berl). 2022 Mar;100(3):463-470. doi: 10.1007/s00109-021-02114-x. Epub 2021 Oct 18.

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.

Eur J Cancer. 2021 Sep;154:66-72. doi: 10.1016/j.ejca.2021.06.008. Epub 2021 Jun 18.

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.

Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.

Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.

Seroconversion rates following COVID-19 vaccination among patients with cancer.

Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.

J Clin Med. 2021 May 14;10(10):2128. doi: 10.3390/jcm10102128.

CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Nat Med. 2021 Jul;27(7):1280-1289. doi: 10.1038/s41591-021-01386-7. Epub 2021 May 20.

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.

Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献